Lifestyle and medication interventions for the prevention or delay of type 2 diabetes mellitus in prediabetes: A systematic review of randomised controlled trials

Australian and New Zealand Journal of Public Health

Volumn 34, Issue 2, 2010, Pages 172-178

  Yuen, Agnes ^a   Sugeng, Yulia ^b   Weiland, Tracey J ^a   Jelinek, George A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Diabetes mellitus; Lifestyle intervention; Pharmacological intervention; Prediabetic state; Prevention and control; Type 2

Indexed keywords

ANTIDIABETIC AGENT;

FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; PREDIABETIC STATE; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77952140670     PISSN: 13260200     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1753-6405.2010.00503.x     Document Type: Article

References (45)

1. World Health Organization [homepage on the Internet]. Geneva(CHE):WHO;2008 [cited 2008 May 20]. Diabetes Programme Facts and Figures: Country and Regional Data. Available from: http://wvww.who.int/diabetes/facts/ world-figures/en/
2. ADA. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care. 1998;21(2):296-309.
3. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007;186(9):461-465
4. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334(299).
5. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes (Cochrane Review): In: The Cochrane Database Systematic Review, 2, 2005. p. 1-80. Oxford (UK): Update Software; 2005.
6. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care. 2005;28(3):736-744
7. Yamaoka K, Tango T. Efficacy of Lifestyle Education to Prevent Type 2 Diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2005;28(11):2780-2786
8. Yates T, Khunti K, Bull F, Gorely T, Davies MJ. The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia. 2007;50:1116-1126
9. Van de Laar FA, Lucassen PLBJ, Akkermans RP, Van de Lisdonk EH, De Grauw WJC. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose (Cochrane Review): In: The Cochrane Database Systematic Review, 4, 2006. Oxford (UK): Update Software; 2006.
10. Padwal R, Laupacis A. Antihypertensive Therapy and Incidence of Type 2 Diabetes: A systematic review. Diabetes Care. 2004;27(1):247-255
11. Norris SL, Zhang X, Avenell A, Gregg E, Bowman B, Schmid CH, et al. Long-Term Effectiveness of Weight-Loss Interventions in Adults with Pre-Diabetes. Am J Prev Med. 2005;28(1): 126-139
12. Knoll T, Narayan S, Coven A, Kmoch J, Byer S, Williams R, et al. Adobe Photoshop CS3. 10 th ed. San Jose (CA): Adobe Systems; 2007.
13. RevMan: Review Manager [computer program]. 5.0 ed. Copenhagen (DNK): The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.
14. Higgins J, Altman D. Chapter 8: Assessing risk of bias in included studies. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.0 [updated February 2008]. Cambridge (UK): The Cochrane Collaboration; 2008.
15. Haahr MT, Hrobjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin Trials. 2006;3(4):360-365
16. Fang Y, Li T, Chen S. Effect of medicine and non-medicine intervention on the outcomes of patients with impaired glucose tolerance - 5-year follow-up. Zhongguo Linchuang Kangfu. 2004;8:6562-6563
17. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289-297
18. Knowler WC, Barrett-Connor E, Fowler S, Hamman RF, Lachin JM, Walker E, et al. Reduction in the Incidence ofType 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346(6):393-403.
19. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072-2077
20. Diabetes Prevention Program [homepage on the Internet]. Rockville (MD): The Biostatistics Center, The George Washington University; 2001 May 18 [cited 2008 Apr 14]. Protocol for the Diabetes Prevention Program. Version 4.4. Available from: http://www.bsc.gwu.edu/dpp/3armprot.htmlvdoc
21. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alphaglucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care. 1998;21(10):1720-1725
22. Diabetes Prevention Program [homepage on the Internet]. Rockville (MD): The Biostatistics Center, The George Washington University; 2006 July 5 [cited 2008 Apr 18]. Protocol for the Diabetes Prevention Program Outcomes Study (DPPOS). Available from: http://www.bsc.gwu.edu/dpp/p2-1.pdf
23. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Hanne-Parikka P, et al. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among subjects with Impaired Glucose Tolerance. N Engl J Med. 2001;344(18):1343-1350 (Pubitemid 32378388)
24. DPPRG. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003;26(4):977-980
25. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102-2107
26. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Intervention. Version 5.0.0. [updated February 2008]. Cambridge (UK): The Cochrane Collaboration; 2008.
27. Mühlhauser I, Kasper J, Meyer G, Federation of European Nurses in D. Understanding of diabetes prevention studies: questionnaire survey of professionals in diabetes care. Diabetologia. 2006;49(8): 1742-1746
28. Tuomilehto J, Wareham N. Glucose lowering and diabetes prevention: are they the same?[see comment]. Lancet. 2006;368(9543):1218-1219
29. Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19(9):708-723
30. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 1999;48(11):2197-2203
31. Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000;49(6):975-980
32. Novoa FJ, Boronat M, Saavedra P, Diaz-Cremades JM, Varillas VF, La Roche F, et al. Differences in Cardiovascular Risk Factors, Insulin Resistance, and Insulin Secretion in Individuals With Normal Glucose Tolerance and in Subjects With Impaired Glucose Regulation: The Telde Study. Diabetes Care. 2005;28(10):2388-2393
33. Guerrero-Romero F, Rodríguez-Morán M. Impaired glucose tolerance is a more advanced stage of alteration in the glucose metabolism than impaired fasting glucose. J Diabetes Complicat. 2001;15(1):34-37
34. Braith RW, Stewart KJ. Resistance Exercise Training: Its Role in the Prevention of Cardiovascular Disease. Circulation. 2006;113(22):2642-2650
35. Kriska AM, Edelstein SL, Hamman RF, Otto A, Bray GA, Mayer-Davis EJ, et al. Physical Activity in Individuals at Risk for Diabetes: Diabetes Prevention Program. Med Sci Sports Exerc. 2006;38(5):826-832
36. Delahanty LM, Conroy MB, Nathan DM. Psychological Predictors of Physical Activity in the Diabetes Prevention Program. JAm Diet Assoc. 2006; 106(5):698-705.
37. Marcus BH, Selby VC, Niaura RS, Rossi JS. Self-efficacy and the stages of exercise behavior change. Res Q Exerc Sport. 1992;63(1):60-66
38. Nishida Y, Suzuki H, Wang DH, Kira S. Psychological determinants of physical activity in Japanese female employees. J Occup Health. 2003;45(1):15-22.
39. ADA. Standards of Medical Care in Diabetes-2008. Diabetes Care. 2008;31 Suppl 1:12-54.
40. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-1679 (Pubitemid 46048554)
41. DPPRG. Achieving Weight and Activity Goals Among Diabetes Prevention Program Lifestyle Participants. Obesity. 2004;12(9):1426-1434
42. Williams R, Rapport F, Elwyn G, Lloyd B, Rance J, Belcher S. The prevention of type 2 diabetes: general practitioner and practice nurse opinions. Br J Gen Pract. 2004;54(504):531-535
43. DPPRG. Within-Trial Cost-Effectiveness of Lifestyle Intervention or Metformin for the Primary Prevention ofType 2 Diabetes. Diabetes Care. 2003;26(9):2518-2523
44. DPPRG.Costs Associated With the Primary Prevention of Type 2 Diabetes Mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;6(1):36-47.
45. Johnson FR, Manjunath R, Mansfield CA, Clayton LJ, Hoerger TJ, Zhang P. High-Risk Individuals' Willingness to Pay for Diabetes Risk-Reduction Programs. Diabetes Care. 2006;29(6):1351-1356